soluble guanylate cyclase stimulator
Jump to navigation
Jump to search
Contraindications
- of no benifit for treatment of left ventricular diastolic dysfunction[1]
Mechanism of action
- stimulates activation of guanylate cyclase
More general terms
More specific terms
Additional terms
References
- ↑ Jump up to: 1.0 1.1 Armstrong PW et al. Effect of vericiguat vs placebo on quality of life in patients with heart failure and preserved ejection fraction: The VITALITY-HFpEF randomized clinical trial. JAMA 2020 Oct 20; 324:1512. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33079152 https://jamanetwork.com/journals/jama/article-abstract/2771900
Udelson JE et al. Effect of praliciguat on peak rate of oxygen consumption in patients with heart failure with preserved ejection fraction: The CAPACITY HFpEF randomized clinical trial. JAMA 2020 Oct 20; 324:1522. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33079154 https://jamanetwork.com/journals/jama/article-abstract/2771902